I think NP mentioned something about x number of months worth of operating capital on hand to uplist. From a SP perspective uplisting would do much more for a truer valuation especially compared to other clinical stage biotechs on NASDAQ. Just use a screener and look at the 100s of clinical stage biotechs trading between 3-40 per a share that do not have half the potential as CytoDyn. One important fact is that most of those bio techs have less than a 100 million outstanding shares. So compared to CytoDyn ~500 million shares and growing to ~ 700 million shares the gap narrows some.